AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2023447 — intervention group
Group type: EXPERIMENTAL
Intervention: Minitracheotomy postoperatively (Group A)
Number of subjects: 30
Study 2023447 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 30
Study 2023447 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 31125576 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib-pravastatin combination (arm A)
Number of subjects: 323
Study 31125576 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone (arm B)
Number of subjects: 323
Study 29565423 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) report
Number of subjects: 200
Study 29565423 — intervention group
Group type: COMPARATOR
Intervention: Family-history report alone
Number of subjects: 200
Study 27287965 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Abstinence Scoring System (NASS; 'Finnegan Scale')
Number of subjects: 131
Study 27287965 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTHER NAS Scale (MNS)
Number of subjects: 131
Study 25239828 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural anticoagulation for specific indications
Number of subjects: 2473
Study 25239828 — intervention group
Group type: COMPARATOR
Intervention: No post-PCI anticoagulation
Number of subjects: 2473
Study 22794223 — intervention group
Group type: EXPERIMENTAL
Intervention: K3 file system
Number of subjects: 30
Study 22794223 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne file system
Number of subjects: 30
Study 22794223 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Adjusting File (SAF)
Number of subjects: 30
Study 22794223 — intervention group
Group type: COMPARATOR
Intervention: SAF as an adjunct after K3
Number of subjects: 30
Study 20700793 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nipradilol
Number of subjects: 146
Study 20700793 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol
Number of subjects: 146
Study 19203070 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐inhibitor quinaprilat 0.5 mg/h administered intravenously via infusion pump
Number of subjects: 70
Study 19203070 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard inotropic‐vasodilator therapy)
Number of subjects: 70
Study 15708700 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels measured at randomization and at 48 hours, 6 weeks, 3 months, and 6 months.
Number of subjects: 1216
Study 15708700 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels predictive of two-year mortality.
Number of subjects: 1216
Study 15708700 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with higher reduction rates of NT-proBNP levels.
Number of subjects: 1216
Study 15708700 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with lower reduction rates of NT-proBNP levels.
Number of subjects: 1216
Study 11861525 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARγ agonists (chronic treatment for 11 days)
Number of subjects: 0
Study 11861525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (14-day treatment)
Number of subjects: 0
Study 11861525 — intervention group
Group type: COMPARATOR
Intervention: Metformin or PPARα agonist (treatment)
Number of subjects: 0
Study 11861525 — intervention group
Group type: COMPARATOR
Intervention: Severe insulin resistance patients (dominant-negative PPARγ mutations)
Number of subjects: 0
Study 10491246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention (handout about ADs + videotape about ADs + procedural aspects and outcomes of CPR)
Number of subjects: 117
Study 10491246 — intervention group
Group type: COMPARATOR
Intervention: Control group (handout about ADs)
Number of subjects: 117
Study 10491246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention
Number of subjects: 117
Study 10491246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 7488811 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (inhaled steroid)
Number of subjects: 31
Study 7488811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 2030065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce treadmill protocol
Number of subjects: 30
Study 2030065 — intervention group
Group type: EXPERIMENTAL
Intervention: Balke treadmill protocol
Number of subjects: 30
Study 2030065 — intervention group
Group type: COMPARATOR
Intervention: Field exercise trial (800-m run)
Number of subjects: 30
Study 7046724 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 30
Study 7046724 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 7046724 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 30
Study 30280515 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% sodium hyaluronate (SH) ophthalmic solution
Number of subjects: 23
Study 30280515 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% sodium hyaluronate (SH) ophthalmic solution
Number of subjects: 23
Study 30280515 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% sodium hyaluronate (SH) ophthalmic solution
Number of subjects: 23
Study 30280515 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 23
Study 30280515 — intervention group
Group type: EXPERIMENTAL
Intervention: All sodium hyaluronate solutions
Number of subjects: 23
Study 30280515 — intervention group
Group type: EXPERIMENTAL
Intervention: All ophthalmic solutions
Number of subjects: 23
Study 27748740 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen
Number of subjects: 150
Study 27748740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 25901590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation-based end-of-life care education
Number of subjects: 187
Study 25901590 — intervention group
Group type: COMPARATOR
Intervention: Classroom-based end-of-life care education
Number of subjects: 187
Study 23999423 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236
Study 23999423 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236
Study 21205435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 23
Study 21205435 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 23
Study 21205435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine and Venlafaxine
Number of subjects: 23
Study 21205435 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 23
Study 19489802 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact for 25 to 120 minutes after birth, early suckling, or both
Number of subjects: 176
Study 19489802 — intervention group
Group type: COMPARATOR
Intervention: Rooming-in after a 2-hour separation
Number of subjects: 176
Study 19489802 — intervention group
Group type: COMPARATOR
Intervention: Swaddling of the infant
Number of subjects: 176
Study 17998498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (PIM completion)
Number of subjects: 40
Study 17998498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PIM completion)
Number of subjects: 40
Study 14994114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 percent isosorbide dinitrate ointment
Number of subjects: 54
Study 14994114 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 54
Study 12074178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-NaFeEDTA group (consuming fortified soy sauce, providing 5 mg Fe/day)
Number of subjects: 304
Study 12074178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-NaFeEDTA group (consuming fortified soy sauce, providing 20 mg Fe/day)
Number of subjects: 304
Study 12074178 — intervention group
Group type: COMPARATOR
Intervention: Control group (consuming non-fortified soy sauce)
Number of subjects: 304
Study 9844789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrexidine (full D1 receptor agonist), single intravenous doses ranging from 2 mg to a maximum of 70 mg infused over 15 or 120 minutes
Number of subjects: 4
Study 9844789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrexidine (full D1 receptor agonist)
Number of subjects: 4
Study 9844789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 4
Study 7865640 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for 5 days
Number of subjects: 12
Study 7865640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing after food
Number of subjects: 12
Study 7865640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2556456 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 80 mg/day
Number of subjects: 6
Study 2556456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 4331769 — intervention group
Group type: EXPERIMENTAL
Intervention: Kethoxal 2.5% cream
Number of subjects: 0
Study 4331769 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 31542942 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide (EQW)
Number of subjects: 14752
Study 28422269 — intervention group
Group type: EXPERIMENTAL
Intervention: Wake therapy
Number of subjects: 64
Study 28422269 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 64
Study 25297637 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐SA (1.5 μg kg(‐1) s.c.)
Number of subjects: 38
Study 25297637 — intervention group
Group type: COMPARATOR
Intervention: peginterferon‐α‐2a (180 μg s.c.)
Number of subjects: 38
Study 23154126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 62
Study 23154126 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PLEX)
Number of subjects: 62
Study 21610124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin treatment
Number of subjects: 372
Study 21610124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 19289135 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-walking exercise (twice weekly for 8 weeks)
Number of subjects: 16
Study 19289135 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 16
Study 19289135 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-walking exercise
Number of subjects: 16
Study 16464138 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Illness Coordinated Care Program (AICCP)
Number of subjects: 275
Study 15482045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 54
Study 15482045 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure plus cognitive restructuring
Number of subjects: 54
Study 11198829 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 218
Study 11198829 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 218
Study 11198829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 11198829 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium 550 mg
Number of subjects: 218
Study 9489517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (GTN)
Number of subjects: 24
Study 9489517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 24
Study 9489517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7999813 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 23
Study 7999813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 23
Study 3075559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 29
Study 3075559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30279194 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR blockade
Number of subjects: 0
Study 28561192 — intervention group
Group type: EXPERIMENTAL
Intervention: No cardiovascular medication
Number of subjects: 18
Study 28561192 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripherally acting medication
Number of subjects: 18
Study 28561192 — intervention group
Group type: COMPARATOR
Intervention: Centrally acting medication
Number of subjects: 18
Study 25565587 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care along with receipt of twice‐daily supportive SMS text messages during the second and third week of the study
Number of subjects: 68
Study 25565587 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 68
Study 23866706 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group CON (compressive optic neuropathy)
Number of subjects: 40
Study 23866706 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group CON
Number of subjects: 40
Study 23866706 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group MP (marked proptosis)
Number of subjects: 40
Study 23866706 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified orbital decompression in group MP
Number of subjects: 40
Study 21179033 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate large loop excision (LLETZ)
Number of subjects: 989
Study 21179033 — intervention group
Group type: COMPARATOR
Intervention: Two to four targeted punch biopsies with recall for LLETZ if necessary
Number of subjects: 989
Study 18855992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 175
Study 18855992 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 175
Study 18855992 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 175
Study 18855992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (2500 U/min)
Number of subjects: 175
Study 18855992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/min)
Number of subjects: 175
Study 18855992 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 175
Study 18855992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 175
Study 17310422 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleretinal imaging group, n = 223
Number of subjects: 448
Study 17310422 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 225
Number of subjects: 448
Study 17310422 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleretinal imaging
Number of subjects: 448
Study 12729114 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation (IF) with two cannulated screws
Number of subjects: 102
Study 12729114 — intervention group
Group type: COMPARATOR
Intervention: Total hip replacement (THR)
Number of subjects: 102
Study 10597556 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane in oxygen/air
Number of subjects: 60
Study 10597556 — intervention group
Group type: COMPARATOR
Intervention: Desflurane in oxygen/nitrous oxide
Number of subjects: 60
Study 8921775 — intervention group
Group type: COMPARATOR
Intervention: High supplementary vitamin E intake (>= 100 IU/day) in the placebo group
Number of subjects: 146
Study 8921775 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with low vitamin E intake
Number of subjects: 146
Study 8921775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E within the drug group
Number of subjects: 146
Study 8921775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C within the drug group
Number of subjects: 146
Study 8921775 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C within the placebo group
Number of subjects: 146
Study 1715740 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 with low-dose steroids
Number of subjects: 110
Study 1715740 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 110
Study 385873 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg oxaprozin given as a single daily dose
Number of subjects: 0
Study 385873 — intervention group
Group type: COMPARATOR
Intervention: 3,900 mg ASA given in 4 equally divided doses
Number of subjects: 0
Study 385873 — intervention group
Group type: EXPERIMENTAL
Intervention: oxaprozin
Number of subjects: 0
Study 31630683 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Lactobacillus fermentum CECT5716 Lc40
Number of subjects: 236
Study 31630683 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Bifidobacterium breve CECT7263
Number of subjects: 236
Study 31630683 — intervention group
Group type: COMPARATOR
Intervention: Standard powdered infant formula (Control group)
Number of subjects: 236
Study 29086988 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD‐40 RV‐only pacing
Number of subjects: 9
Study 29086988 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD‐40 BIV pacing
Number of subjects: 9
Study 29086988 — intervention group
Group type: COMPARATOR
Intervention: VVI‐40 back up pacing
Number of subjects: 9
Study 26192249 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-parent psychotherapy (CPP)
Number of subjects: 159
Study 26192249 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 159
Study 24381967 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of alpha tocopherol
Number of subjects: 613
Study 24381967 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d of memantine
Number of subjects: 613
Study 24381967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alpha tocopherol and memantine
Number of subjects: 613
Study 24381967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 22073938 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-particle abrasion with 50 μm Al(2)O(3) (0.4-0.7 MPa) during 20 s
Number of subjects: 48
Study 22073938 — intervention group
Group type: COMPARATOR
Intervention: Mechanical retentions with carbide burrs
Number of subjects: 48
Study 22073938 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycling (500 cycles, 5-55°C) applied to both groups
Number of subjects: 48
Study 22073938 — intervention group
Group type: COMPARATOR
Intervention: Thermocycling not applied
Number of subjects: 48
Study 20024737 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of oral health with HIV primary care providers
Number of subjects: 0
Study 20024737 — intervention group
Group type: EXPERIMENTAL
Intervention: Five or more primary care visits in the past year
Number of subjects: 0
Study 20024737 — intervention group
Group type: EXPERIMENTAL
Intervention: Illicit drug use among men
Number of subjects: 0
Study 20024737 — intervention group
Group type: EXPERIMENTAL
Intervention: Each additional health topic discussed
Number of subjects: 0
Study 17166765 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS(SH)
Number of subjects: 6
Study 17166765 — intervention group
Group type: COMPARATOR
Intervention: cTBS(IH)
Number of subjects: 6
Study 17166765 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study 16400234 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with aluminium hydroxide adsorbed house dust mite allergoid
Number of subjects: 40
Study 16400234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11985408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat, low-cholesterol diet (intervention group)
Number of subjects: 307
Study 11985408 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet (control group)
Number of subjects: 307
Study 9790206 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided subclavian vein catheterization using the Smart Needle
Number of subjects: 240
Study 9790206 — intervention group
Group type: COMPARATOR
Intervention: Standard subclavian vein catheterization
Number of subjects: 240
Study 7714640 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nursing and homemaker services; individualized support and education
Number of subjects: 0
Study 7714640 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemaker assistance during the first 8 weeks after discharge
Number of subjects: 0
Study 3067179 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45
Study 3067179 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections (MI)
Number of subjects: 45
Study 3067179 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 45
Study 29688838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL) treatment applied directly on the eyelids, with three treatments at 4-week intervals.
Number of subjects: 44
Study 29688838 — intervention group
Group type: COMPARATOR
Intervention: Sham IPL treatment (control group).
Number of subjects: 44
Study 28556458 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention (provision of hardware: bin for solid waste, 4 l flushing bucket, 70 l water reservoir; behaviour change communication: compound meetings, interpersonal household sessions, signs depicting rules for toilet use)
Number of subjects: 1226
Study 28556458 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Number of subjects: 1226
Study 26542698 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP-derived parameters (ischemic-core volume, percentage ischemic core, penumbra volume)
Number of subjects: 175
Study 26542698 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP-derived parameters (percentage ischemic core)
Number of subjects: 175
Study 26542698 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP-derived parameters (penumbra volume)
Number of subjects: 175
Study 22926459 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific timely appointments for triage (STAT)
Number of subjects: 971
Study 22926459 — intervention group
Group type: COMPARATOR
Intervention: Control site (triaged waitlist)
Number of subjects: 971
Study 20865582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at 0.5 mcg/kg/hour during operation
Number of subjects: 40
Study 20865582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (9% NaCl at the same rate and volume)
Number of subjects: 40